Advancell raised $315 million in an oversubscribed Series D to accelerate its integrated radiopharmaceutical push, pairing late-stage clinical development with isotope supply and manufacturing infrastructure. The funding is earmarked to support Phase III development of ADVC-001, a lead-212 prostate-specific membrane antigen-targeted radioligand therapy for metastatic castration-resistant prostate cancer. The round highlights how capital continues to concentrate in radiopharma models that can address both clinical execution and “supply chain physics” for short-lived isotopes. Company disclosures position Advancell as moving toward full-stack capabilities rather than relying solely on external isotope sourcing. For the sector, the size and focus of the financing signal that manufacturing readiness and isotope availability are becoming key differentiators as radioligand programs progress toward pivotal readouts.